FDA accepts Pfizer's application for pneumococcal conjugate vaccine

 

• Under priority review status, the FDA has accepted to review Pfizer's (NYSE:PFE) 20-valent pneumococcal conjugate vaccine for the prevention against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, in adults ages 18 years and older.

• Agency's goal date for a decision is in June 2021.

• https://seekingalpha.com/news/3642700-fda-accepts-pfizers-application-for-pneumococcal-conjugate-vaccine